MedTrace Logo

Tofacitnib for the Treatment of Alopecia Areata and Variants

NCT02197455 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Conditions

  • Alopecia Areata (AA)
  • Alopecia Totalis (AT)
  • Alopecia Universalis (AU)

Interventions

DRUG

Tofacitinib Administration

5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Brett King, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197455 on ClinicalTrials.gov